Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CDK11B | P21127 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.32 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7990875 | 0.86 | SMN1; SMN2 (0.44) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1514013 | 0.85 | SMN1; SMN2 (0.43) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| SCHEMBL1514068 | 0.79 | GSK3B (0.42) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| SCHEMBL3609188 | 0.76 | SMN1; SMN2 (0.43) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| SCHEMBL8043519 | 0.69 | SMN1; SMN2 (0.41) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30286292 | 0.67 | CSNK1D (0.43) | ALDH1A1ADORA2AIKBKBCDK11BCDK7 | |
| SCHEMBL10270155 | 0.64 | CCNA2 (0.51) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3603250 | 0.64 | DPP7 (0.49) | GSK3BGSK3ADYRK1ACLK4HRH4 | |
| SCHEMBL6609299 | 0.62 | GSK3B (0.56) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 | |
| SCHEMBL10270734 | 0.61 | MAPT (0.45) | GSK3BSMN1; SMN2CCNA2CDK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| EP-2137188-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Pharma AG (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-2137188-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | CACNA1B 805/4885GSK3B 2707/4885SMN1; SMN2 3215/4885 |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | CACNA1B 1935/4885GSK3B 3829/4885SMN1; SMN2 1622/4885 |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | CACNA1B 3650/4885GSK3B 3269/4885SMN1; SMN2 1461/4885 |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | THPO, TYMP, TPMT | CACNA1B 3573/4885GSK3B 3009/4885SMN1; SMN2 1085/4885 |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | CACNA1B 1935/4885GSK3B 3829/4885SMN1; SMN2 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.